Literature DB >> 8600493

Benzodiazepine use in the elderly prior to psychiatric hospitalization.

M H Zisselman1, B W Rovner, Y Shmuely.   

Abstract

The objective of this study was to assess benzodiazepine use and the treatment of depression before admission to an inpatient geriatric psychiatry unit in a sample of elderly patients. The study design was a retrospective chart review, and the setting was a university hospital inpatient geriatric psychiatry unit. The subjects included 131 consecutively admitted patients. Preadmission benzodiazepine drug regimens were reviewed in relation to the Health Care Financing Administration (HCFA) guidelines for benzodiazepine use in nursing homes and in relation to psychiatric diagnoses. Psychiatric diagnoses were made based on DSM-III-R criteria. The preadmission benzodiazepine regimens of 38 of 59 patients receiving benzodiazepines (64.0%) were outside the HCFA guidelines. Also, 30 of 76 patients (39.5%) with depressive disorders received benzodiazepines as sole treatment of depression prior to their admission. This study suggests that benzodiazepines may be misused in the elderly and indicates the need for education and research on the appropriate use of benzodiazepines in the treatment of depression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8600493     DOI: 10.1016/S0033-3182(96)71596-7

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  3 in total

Review 1.  Pharmacologic treatment of depression in late life.

Authors:  A J Flint
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

Review 2.  Comorbidity of depression and anxiety in the elderly.

Authors:  Eric J Lenze
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

3.  [Suitability of the use of benzodiazepines prescribed by the pharmacist in the elderly. A doctor-pharmacist collaboration study].

Authors:  Josefina Velert Vila; M del Mar Velert Vila; Luis Salar Ibáñez; Juan Antonio Avellana Zaragoza; Lucrecia Moreno Royo
Journal:  Aten Primaria       Date:  2011-10-24       Impact factor: 1.137

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.